Advice
Medicine withdrawn
In August, 2024, the Marketing Authorisation for belantamab mafodotin (Blenrep), for the indication noted below, was withdrawn.
Medicine details
- Medicine name:
- belantamab mafodotin (Blenrep)
- SMC ID:
- SMC2597
- Indication:
Monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 15 January 2024
Additional notes
In August, 2024, the Marketing Authorisation for belantamab mafodotin (Blenrep) was withdrawn.